LDN-27219 CANCER TREATMENT RESEARCH - AN OVERVIEW

Just one especially exciting compound is LDN-27219. When most tTG inhibitors are intended to bind into the protein crosslinking Energetic internet site, LDN-27219 as a substitute binds towards the nucleotide binding pocket from the enzyme while it is in its shut-state conformation, and stabilizes that conformation to prevent crosslinking activity.7